# Guardant Health Palo Alto precision-oncology company (founded 2012 by Helmy Eltoukhy and AmirAli Talasaz) that pioneered "liquid biopsy" — detecting cancer from DNA fragments in blood. It matters to this KB as the current chapter of the [[Alex Azar]] [[Revolving Door]] story and as a case study in how Medicare coverage rulemaking, not drug pricing, is becoming the high-margin frontier where former regulators are most valuable. ## The Shield Test In July 2024, Guardant's **Shield** became the first blood test approved by the [[FDA]] as a *primary* screening option for colorectal cancer (adults 45+, average risk). In the pivotal ECLIPSE trial it showed 83% sensitivity for detecting existing cancers — but much weaker performance on advanced precancerous polyps, the lesions whose removal actually *prevents* cancer. That gap is the core of the medical controversy: a convenient test that finds cancer late beats an inconvenient one that prevents it never being taken, argues Guardant; critics counter that taxpayers shouldn't pay a premium for inferior prevention. Shield reimburses at $1,495 per test under Medicare's ADLT pathway (versus roughly $500 for stool-based tests), covered every three years. ## The Azar Conflict [[Alex Azar]] — the former HHS Secretary whose old department contains CMS — joined Guardant's board in September 2025, with compensation valued around $725,000 per year in cash, options, and restricted stock. In June 2026, reporting by The Center Square and others noted that a pending **[[CMS]] proposal to expand national coverage standards for blood-based colorectal screening** stood to materially benefit Shield, with doctors and former officials filing comments objecting that the framework rewards late detection over prevention. No illegality is alleged; the story's value is structural — it shows the [[Revolving Door]] operating in the diagnostics/coverage arena exactly as it long has in drug pricing, with the same personnel. ## Connections - [[Alex Azar]] — Board member since September 2025; former secretary of the department that decides Shield's Medicare fate - [[Revolving Door]] — The mechanism on display - [[Big Pharma]] — Hub page; "watch for" section tracks this rulemaking - [[Department of Health and Human Services]] — Parent of CMS, the decision-maker